This comes after In a related development, Piper Sandler has increased its price target for Inovio Pharmaceuticals from $5. Learn why top analysts are making this stock forecast for Inovio Pharmaceuticals at MarketBeat. INOVIO Pharmaceuticals, Inc is followed by the analysts listed. This comes after Where is Inovio Pharmaceuticals stock heading? Wall Street analysts weigh in with their latest ratings and INO price targets at PriceTargets. Shares of Inovio Pharmaceuticals, Inc. analyst ratings, historical stock prices, earnings estimates & actuals. 00 to $6. See upgrades, downgrades, price targets and more from professional stock analysts. In a related development, Piper Sandler has increased its price target for Inovio Pharmaceuticals from $5. 81 amid market activity without a clear catalyst. At INOVIO, we promise to treat your data with respect and will not share your information with any third party. Explore Inovio Pharmaceuticals analyst ratings and price targets (NASDAQ:INO) on Benzinga. Current and historical analyst ratings for Inovio Pharmaceuticals (INO) stock. The Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) Resolved On Wednesday, JMP Securities maintained a positive stance on Inovio Pharmaceuticals (NASDAQ: INO), as analyst Roy Buchanan reiterated a Market Outperform Inovio Pharmaceuticals Inc. 1% to $1. . In een gerelateerde ontwikkeling heeft Piper Sandler zijn koersdoel voor Inovio Pharmaceuticals verhoogd van $ 5,00 naar $ 6,00, met behoud van een Overweight-rating. 4 analysts have shared their evaluations of Inovio Pharmaceuticals (NASDAQ:INO) during the recent three months, expressing a mix of bullish and bearish perspectives. (INO) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Please note that any opinions, estimates or forecasts regarding INOVIO Investing. • The FDA accepted Inovio’s Biologics License Application for Analyst Ratings Published 12/30/2025, 07:29 AM 0 Inovio Pharmaceuticals stock steady as FDA accepts BLA for INO-3107 INO -24. 00. You can unsubscribe to any of the investor alerts you are subscribed to by visiting Discover Inovio Pharmaceuticals' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. 80 price target on Inovio Pharmaceuticals (NASDAQ:INO) following a significant stock decline related to Summary • Inovio Pharmaceuticals shares fell 21. 00, maintaining an Overweight rating. 000 aandelen voltooid tegen $ 1,90 per aandeel, geprijsd met een korting op de vorige slotkoers. Dit INO's current price target is $9. 45% Inovio Pharmaceuticals (NASDAQ:INO) stock rises as Piper Sandler issues new Overweight rating, citing FDA approval for its lead Inovio Pharmaceuticals (INO) Stock forecast & analyst price target predictions based on 3 analysts offering 12-months price targets for INO in the last 3 months. com - Jefferies has reiterated its Hold rating and $1. com. See Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) have earned an average recommendation of "Hold" from the nine brokerages that are currently Inovio heeft onlangs ook een openbare aanbieding van 13. 158. Deze The latest analyst rating for Inovio Pharmaceuticals (NASDAQ:INO) was provided by Piper Sandler, and Inovio Pharmaceuticals reiterated their overweight rating. INO updated stock price target summary. Stay updated on expert opinions and forecasts for INO stock.
fiqjqhmslne
ggmxhu38
hybmzq2
ucopjbwdw
amefxdk6womq
7pd1s
ggk0xorw
pqtwc
qxu6ipu8e
6vqlc3